Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial - Goebeler, M.; Bata‐Csörgő, Z.; De Simone, C.; Didona, B.; Remenyik, E.; Reznichenko, N.; Stoevesandt, J.; Ward, E.S.; Parys, W.; Haard, H.; Dupuy, P.; Verheesen, P.; et al. (British journal of dermatology (1951), 2022)
Keywords: Adverse events; Antibodies, Monoclonal, Humanized - adverse effects; Autoantibodies; Autoimmune diseases; Corticosteroids; Desmoglein 1; Disease control; Dosage; Fc receptors; Feasibility Studies; Histocompatibility Antigens Class I; Humans; Immunoglobulin G; Infant, Newborn; Mucosa; Neonates; Newborn babies; Patients; Pemphigus; Pemphigus - drug therapy; Prednisone; Prednisone - administration & dosage; Receptors, Fc; Remission; Remission (Medicine); Skin diseases